BACE1 and spinal muscular atrophy, type 1: Only in SMA type 1 patients, a change of both BACE‐1 and alpha‐synuclein levels at day 180 significantly correlated with a change in the CHOP INTEND score at treatment day 300 (p = 0.040 and p = 0.013, respectively).